|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
EBSCO_ocn969646412 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr |n|---||||| |
| 008 |
170121s2016 xx o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d MERUC
|d OCLCQ
|d N$T
|d OCLCF
|d AGLDB
|d OCLCQ
|d D6H
|d VTS
|d OCLCQ
|d STF
|d OCLCQ
|d AJS
|d OCLCO
|d OCLCQ
|
| 066 |
|
|
|c (S
|
| 019 |
|
|
|a 1264956988
|
| 020 |
|
|
|a 9781681081632
|q (electronic bk.)
|
| 020 |
|
|
|a 1681081636
|q (electronic bk.)
|
| 029 |
1 |
|
|a DEBSZ
|b 493180745
|
| 029 |
1 |
|
|a AU@
|b 000065562012
|
| 035 |
|
|
|a (OCoLC)969646412
|z (OCoLC)1264956988
|
| 050 |
|
4 |
|a RM345
|b .F766 2016
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 615.71
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Frontiers in cardiovascular drug discovery.
|n Volume 3 /
|c edited by Atta-ur-Rahman & M. Iqbal Choudary.
|
| 260 |
|
|
|a Sharjah :
|b Bentham Science Publishers,
|c 2016.
|
| 300 |
|
|
|a 1 online resource (406 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Frontiers in Cardiovascular Drug Discovery ;
|v v. 3
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|6 880-01
|a PREFACE; List of Contributors ; P2Y12-Receptor Antagonists and the Concept of Tailored Strategy ; INTRODUCTION; ADP RECEPTORS; P2Y12 RECEPTOR; P2Y12 INHIBITORS; Thienopyridines; Ticlopidine; Clopidogrel; Prasugrel; Ticagrelor; Cangrelor; Elinogrel; BX 667; THE CONCEPT OF PERSONALIZED THERAPY; Factors Influencing Clopidogrel Variability; Anti-Platelet Function Testing; Platelet Aggregometry; Flow Cytometry; Shear-Dependent Assay; Platelet Counting; Thrombelastography; Anti-Platelet Function Testing & Clinical Impact; Genotype Testing; Genetic Testing & Clinical Impact.
|
| 505 |
8 |
|
|a Vasopressin and the Cardiovascular System: Receptor Physiology and Clinical Implications INTRODUCTION; HISTORICAL ASPECTS; PHYSIOLOGY OF VASOPRESSIN; Structure of Vasopressin and Related Peptides; Structure of Vasopressin; Structure of Related Peptides; Synthesis of Vasopressin; Metabolism; Factors Affecting Vasopressin Release; Osmoregulation; Baroregulation; Neurohormonal Stimuli; Plasma Levels of Vasopressin; Vasopressin Levels in Health; Vasopressin Levels During Illness; Measurement of Plasma Vasopressin Levels; Vasopressin Receptors; Receptor Structure; Receptor Subtypes; V1A Receptor.
|
| 505 |
8 |
|
|a V1B€or V3 ReceptorV2€Receptor; Oxytocin Receptor; Purinergic Receptors; Down Regulation of Vasopressin Receptors; Systemic Effects of Vasopressin; Renal Effects; Vasoconstrictor Effects; Vasodilator Effects; Effects of Vasopressin on Heart; Endocrine Effects; Effects on Coagulation System; Other Effects; Therapeutic Applications of Vasopressin; Nocturnal Enuresis; Diabetes Insipidus; Bleeding Abnormalities; Oesophageal Varices Haemorrhage; Abdominal Distension & Abdominal X-ray; Vasodilatory Shock States; Hemorrhagic Shock; Other Uses; Future; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS.
|
| 504 |
|
|
|a REFERENCES.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Cardiovascular agents.
|
| 650 |
|
2 |
|a Cardiovascular Agents
|
| 650 |
|
6 |
|a Agents cardiovasculaires.
|
| 650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a Cardiovascular agents.
|2 fast
|0 (OCoLC)fst00847147
|
| 700 |
1 |
|
|a Atta-ur-Rahman.
|
| 700 |
1 |
|
|a Choudhary, M. Iqbal.
|
| 776 |
0 |
8 |
|i Print version:
|a Atta-ur-Rahman.
|t Frontiers in Cardiovascular Drug Discovery Volume 3.
|d Sharjah : Bentham Science Publishers, ©2016
|z 9781681081649
|
| 830 |
|
0 |
|a Frontiers in Cardiovascular Drug Discovery.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1511899
|z Texto completo
|
| 880 |
8 |
|
|6 505-00/(S
|a Inter-Individual Variability of New P2Y12 InhibitorsPersonalized Therapy; CONCLUSION; ABBREVIATIONS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Evolution of Heart Failure Pharmacotherapy ; INTRODUCTION; CHRONIC SYSTOLIC HEART FAILURE; β-Blockers; Beta Blockers and Special Populations; Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin Receptor Blockers (ARBs) ; Diuretics; Aldosterone Antagonists; Digoxin; Hydralazine/Isosorbide Dinitrate; Ivabradine; Polyunsaturated Fatty Acids (PUFA); Statins; ACUTE DECOMPENSATED HEART FAILURE; Classification; Management; Diuretics.
|
| 880 |
8 |
|
|6 505-01/(S
|a Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin Receptor Blockers (ARBs) β-blockers; Aldosterone Antagonists; Vasopressin Antagonists ; Vasodilators ; Natriuretic Peptides; Inotropes; Novel Agents for Acute Decompensated Heart Failure in Development; HEART FAILURE WITH PRESERVED EJECTION FRACTION; β-Blockers; Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin Receptor Blockers (ARBs) ; Calcium Channel Blockers; Digoxin; Aldosterone Antagonists; MISCELLANEOUS DRUG THERAPIES; CONCLUSION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES.
|
| 936 |
|
|
|a BATCHLOAD
|
| 938 |
|
|
|a EBL - Ebook Library
|b EBLB
|n EBL4768333
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 1511899
|
| 994 |
|
|
|a 92
|b IZTAP
|
